Outcomes of de novo belatacept-based immunosuppression regimen and avoidance of calcineurin inhibitors in recipients of kidney allografts at higher risk for underutilization

Nephrology (Carlton). 2022 Dec;27(12):1006-1007. doi: 10.1111/nep.14120. Epub 2022 Oct 17.

Authors

Gregory Petrossian¹, Jorge Ortiz¹, Alejandro Chiodo Ortiz¹, Naoru Koizumi², Robert Plews¹

Affiliations

¹ Section of Renal and Pancreatic Transplant Services, Albany Medical Center, Albany, New York, USA.
² Schar School of Policy and Government, George Mason University, Fairfax, Virginia, USA.

PMID: 36251149
DOI: 10.1111/nep.14120

No abstract available

Publication types

Letter
Comment

MeSH terms

Abatacept / adverse effects
Allografts
Calcineurin Inhibitors* / adverse effects
Graft Rejection / prevention & control
Graft Survival
Humans
Immunosuppression Therapy*
Immunosuppressive Agents / adverse effects
Kidney

Substances

Calcineurin Inhibitors
Abatacept
Immunosuppressive Agents